CER Daily Newsfeed

Real-World Data Back GLP-1s in Asthma, Cardiopulmonary Conditions

(10/24, Crystal Phend, Medpage Today) reports “...For type 2 diabetes patients with OSA, GLP-1 receptor agonists were associated with reduced risk of intubation compared with DPP-4 inhibitors (HR 0.603, 95% CI 0.548-0.664) and metformin (HR 0.814, 95% CI 0.73-0.906), reported Martin Borissov, MD, of the University of Maryland School of Medicine in Baltimore. New-onset COPD was also less likely for GLP-1 drug users compared with metformin (HR 0.886, 95% CI 0.838-0.936) and sulfonylureas (HR 0.812, 95%CI 0.777-0.848). No differences were seen compared with SGLT-2 inhibitors or thiazolidinediones (TZDs).” Full

New Legislation In Works From Senate Working Group To Rein In 340B Misuses

(10/23, Gabrielle Wanneh, Inside Health Policy) reports “...According to [GAO Director of Health Care Michelle Rosenberg], [HRSA] has not ensured it has reliable data to determine if participating hospitals are non-profits, a key eligibility requirement. HRSA has also not verified that non-governmental hospitals, which comprise two thirds of the hospitals participating in the program, have a contract with the state or local government to provide services to low-income individuals not eligible for Medicare or Medicaid, which is required by law, she added.” Subscription Required